Price (delayed)
$11.63
Market cap
$634.96M
P/E Ratio
13.68
Dividend/share
N/A
EPS
$0.85
Enterprise value
$360.07M
Stoke Therapeutics, is a biotechnology company dedicated to addressing the underlying cause of severe diseases by up-regulating protein expression with RNA-based medicines. Using the company's proprietary TANGO (Targeted Augmentation of
There are no recent dividends present for STOK.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.